Semaglutide or tirzepatide — how the choice gets made

Most people who ask us about these medications arrive with a brand name in mind. A friend lost weight on Ozempic, a coworker started Zepbound, the television keeps advertising Wegovy, and the internet has decided Mounjaro is the strong one. It can look like a choice among four drugs ranked from gentle to powerful.

Behind those four names are only two molecules, close relatives working on the same gut-hormone system. Which one fits depends less on strength than on whose history, labs, and digestion we are talking about.

What GLP-1 and GIP actually do

Both medications imitate incretins, hormones the gut releases when food arrives. Together they tell the pancreas a meal is underway, so it releases insulin in proportion to the sugar actually present, which is why, on their own, these drugs rarely push blood sugar too low. GLP-1 also restrains glucagon, the hormone that tells the liver to release stored sugar.

The effects people feel come from two further actions. GLP-1 slows the stomach’s emptying, so fullness arrives sooner and lasts longer. And through receptors in the brainstem and hypothalamus, it lowers the drive to eat. Receptors also sit in reward circuitry, which is likely why what patients call “food noise” — intrusive, repetitive thoughts about the next meal — fades.

Your own GLP-1 is broken down almost immediately by an enzyme called DPP-4; both drugs are built to resist it and ride on albumin in the blood, so the signal holds between doses. Semaglutide activates the GLP-1 receptor; tirzepatide, built on the structure of GIP, is a dual agonist that activates both receptors. GIP adds its own insulin-releasing signal and appears to act on fat tissue and on the brain’s appetite and nausea centers; its exact contribution is still being worked out.

Four familiar names, two molecules

Ozempic and Wegovy both contain semaglutide; Mounjaro and Zepbound both contain tirzepatide. What differs is the FDA-approved use: Ozempic and Mounjaro for type 2 diabetes, Wegovy and Zepbound for chronic weight management in adults with obesity, or with overweight and a weight-related condition. Semaglutide also comes as a daily tablet, Rybelsus or Wegovy; tirzepatide is injection-only. Additional approvals can tip the choice: Ozempic and Mounjaro to lower heart attack and stroke risk in type 2 diabetes with cardiovascular disease, and Ozempic to slow kidney disease; Wegovy to lower that risk in adults with established cardiovascular disease and excess weight, and for a form of fatty liver disease with moderate to advanced scarring; Zepbound for moderate to severe obstructive sleep apnea in adults with obesity.

These are never combined: not semaglutide with tirzepatide, and not one drug under two brands. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as these brand-name products.

How the two compare

In head-to-head research, tirzepatide has produced greater average weight loss than semaglutide, and in type 2 diabetes a somewhat larger drop in A1c, though both lower it substantially. The difference is real, and it is where “the stronger one” comes from. But an average describes a group, not a person. Individual responses to either drug vary widely, and a modest response to one does not settle how someone would do on the other.

Strength is only part of the question. The rest is which one fits your history, your labs, and the way your body responds.

The side effects are similar in kind and dominated by the gut: nausea, vomiting, early fullness, burping and reflux, stomach pain, constipation or diarrhea, and an appetite so quiet that some people under-eat, protein included. Because both slow the stomach, tell your surgeon or anesthesiologist before any procedure involving sedation. One practical difference: tirzepatide can make birth control pills less reliable after starting and after each dose increase, and its label advises a backup or non-oral method during those stretches.

What matters in the choice

Some of it decides whether either drug is appropriate at all; the rest decides which one:

• History and labs. A1c, fasting glucose and insulin, lipids, kidney function, and a thyroid panel. Whether you have type 2 diabetes, prediabetes, heart or kidney disease, or sleep apnea shapes which label fits. Fasting insulin often climbs long before glucose does, so a value in the gray area, where functional ranges vs regular laboratory ranges matter, can mean the pancreas is already working hard. Very high triglycerides can cause pancreatitis on their own, and kidney function shows how much margin there is if vomiting or diarrhea leads to dehydration. With type 2 diabetes, diabetic eye disease matters too, since a steep drop in A1c can temporarily worsen it. Taking insulin or a sulfonylurea raises the low-blood-sugar risk with either drug, which we coordinate with your prescribing doctor.
• Medullary thyroid carcinoma or MEN2. A personal or family history of medullary thyroid carcinoma, a rare cancer of the thyroid’s C-cells, or having multiple endocrine neoplasia type 2 (MEN2) is a contraindication for both drugs, as is a prior serious allergic reaction to either one. The warning comes from thyroid tumors in rodents; whether it applies to people is unknown, but the line is firm. Ordinary hypothyroidism or Hashimoto’s does not, by itself, rule either out.
• Pancreas and gallbladder. A past episode of pancreatitis changes the conversation: both drugs’ labels carry a pancreatitis warning, the major trials left out people with chronic or recent pancreatitis, and after an episode either drug is used only with real caution, if at all. Gallbladder history matters too, because substantial weight loss raises the risk of gallstones on its own and gallbladder disease is a listed risk for both.
• Pregnancy plans. Neither drug is used for weight loss in pregnancy, and semaglutide lingers in the body, so if pregnancy or breastfeeding is in your plans, the timing is something to map out well ahead with your prescriber. Weight loss can also restore ovulation in people whose cycles were irregular, which, with tirzepatide’s effect on the pill, makes contraception part of the plan.
• Tolerability and prior response. If you have taken either before, the details matter: how far the dose went, whether nausea capped it, whether the response stalled, or whether you stopped only over cost or a shortage. Gastroparesis or significant reflux counts too, since both drugs slow the stomach further.
• Access and cost. Coverage varies by plan, brand, and diagnosis, and prices differ, but the label follows the diagnosis, never the coverage. Access still matters clinically: the better drug on paper is not the better drug if you cannot get it consistently, and a long gap often means rebuilding the dose from a lower step.

Whichever drug is chosen, get prompt medical care for severe stomach pain that persists, sometimes reaching the back; upper-stomach pain with fever or yellowing skin or eyes; vomiting or diarrhea that will not let up; or a neck lump, hoarseness, or trouble swallowing. Swelling of the face, lips, or throat, or trouble breathing, needs emergency care.

The foundation matters with either one

Neither molecule protects muscle, makes up for short sleep, or teaches a new way of eating. Part of any large weight loss is lean tissue, and more muscle goes when the body has no reason to keep it: protein at every meal and regular resistance training give it one. Short or broken sleep raises ghrelin, the hunger hormone, and lowers leptin, the fullness signal, working against the medication. Untreated sleep apnea is worth ruling out. These habits also shape whether the result holds after coming off a GLP-1.

How you eat also affects how well either drug is tolerated, and tolerability often decides which one you can stay on. With the stomach emptying slowly, large or greasy meals are the usual triggers for nausea and reflux. In Chinese medicine, this picture reads as Stomach Qi failing to descend — Qi meaning the body’s functional activity, here digestion’s downward movement — and acupuncture, long used for nausea, is something we sometimes add as support.

A choice, not a commitment

Starting one medication does not lock anyone in. If side effects do not settle, the response stalls, or coverage changes, switching is a reasonable step, made with the prescribing clinician, not on your own, and planned in stages: there is no simple dose-for-dose conversion between the two.

How we approach it

A first conversation starts with the history: your weight over the years, what has and has not worked, your digestion, and every medication and supplement you take. Then the labs, so we are collecting all the pieces of the puzzle — including drivers neither medication will fix, such as a sluggish thyroid, which a functional medicine workup can bring to the surface. If either one fits, the prescription comes from a licensed prescribing clinician, and we coordinate with them as the dose is started low and adjusted.

Semaglutide and tirzepatide are prescription medications that require a medical evaluation and ongoing supervision. If you are weighing the two, contact us and bring any recent labs.

The journal is written by Dr. Nazzar from the practice. Articles reflect clinical observation and current research, not personalized medical advice. To explore your own case, schedule a consultation.